Trump pulls Heidi Overton’s nomination to lead FDA

ERIC LEE/THE NEW YORK TIMES
Dr. Heidi Overton, deputy assistant to the president for domestic policy, at the White House on April 3. If confirmed by the Senate, Overton would succeed Dr. Marty Makary, who resigned as commissioner of the Food and Drug Administration in May 2026. President Donald Trump withdrew the nomination of Overton to lead the Food and Drug Administration due to insufficient support in Congress, according to a White House official.
WASHINGTON >> President Donald Trump withdrew the nomination of Heidi Overton to lead the Food and Drug Administration due to insufficient support in Congress, according to a White House official.
A pivotal Senate committee led by Bill Cassidy, a Louisiana Republican and physician, was due to vote on her nomination this morning. Republicans’ one-vote advantage on the panel left the nomination vulnerable to a single GOP defection.
The White House is weighing Senator Roger Marshall of Kansas, a former obstetrician who recently lost his reelection bid, as a replacement nominee, according to two people familiar with the matter.
Overton’s nomination was fraught from the outset and the withdrawal followed weeks of uncertainty as opponents criticized her views on vaccines and abortion and questioned her ties to industry.
Trump nominated Overton, a preventive medicine physician and deputy director of the White House Domestic Policy Council, in August, three months after the resignation of former FDA Commissioner Marty Makary.
Some Trump officials working on Overton’s nomination began to doubt whether she had enough support among Senate Republicans after the party faced sweeping losses in this month’s midterm elections, costing them control of the House of Representatives and the Senate next year.
Don't miss out on what's happening!
Stay in touch with breaking news, as it happens, conveniently in your email inbox. It's FREE!
By clicking to sign up, you agree to Star-Advertiser's and Google's Terms of Service and Privacy Policy. This form is protected by reCAPTCHA.
Several members of the Senate Health, Education, Labor and Pensions Committee, including Cassidy, Susan Collins of Maine and Marshall, lost their reelection bids.
Cassidy, who had been undecided on Overton and had previously criticized her involvement in the Trump administration’s efforts to roll back childhood vaccination, on Tuesday evening said she had won his confidence.
In a tweet, Cassidy said he had been having productive conversations with members of Congress and that he believed she had the support in the committee and the larger Senate needed for confirmation.
He said the FDA head would be decided by the next Democratic-led Senate.
Overton had appeared with Trump in August during an event touting an executive order that called for reducing the number of federally recommended childhood vaccinations and breaking up the measles, mumps and rubella, or MMR, vaccine into three separate shots.
Overton’s support of that order unnerved several medical groups and career FDA officials and further complicated her path, according to two other people familiar with the conversations.
Cassidy said today at the committee meeting that the group also would not be voting on a second Trump nominee: Health Secretary Robert F. Kennedy Jr.’s former No. 2 Jim O’Neill.
The Trump administration had nominated O’Neill to lead the National Science Foundation after he served briefly as acting director of the US Centers for Disease Control and Prevention and then left the health department in February.
Cassidy, who has wrangled with Kennedy over his anti-vaccine policies and statements, told his committee that O’Neill had failed to do enough to “stand up for science and against irresponsible decisions and statements from Secretary Kennedy.”
Democrats were also critical of the openly anti-abortion stance by Overton and her views on the abortion pill mifepristone. Overton has criticized the loosening of mifepristone dispensing restrictions under the Biden administration. The FDA is currently conducting a safety review of the medication that has been used by millions of women since its approval in 2000, which it said will conclude by March 2027.
Influential supporters of Kennedy’s “Make America Healthy Again” movement criticized Overton’s ties to corporations they oppose.
Overton had also drawn fire over vaping. A nonpartisan advocacy group called Health in Office launched a campaign on Friday branding her “Heidi Vaperton,” with posters and yard signs depicting her holding a vape and urging senators to “say no” to her candidacy going up across Washington and other cities.
At her September confirmation hearing, Overton defended the FDA’s May authorization of fruit-flavored vapes, saying there was evidence that flavored vapes could help some adults quit smoking.
FDA Deputy Commissioner for Food Kyle Diamantas is currently serving as acting commissioner.
Additional reporting by Ryan Jones.
Ver nota original ↗
¿Querés un resumen rápido de esta noticia, hecho por nuestra IA?
